Anavex Life Sciences Corp (AVXL)

[Alinea818]

CTAD CONFERENCE ON SAT 9:30am Axovant ///// 9:45am Anavex
At 9:30am Axovant is presenting RVT-101 (review of the preclinical & clinical results & status of the Development program.

At 9:45am ANAVEX (right after axovant present) New Exploratory Alzheimer's Drug Anavex 2-73: Assessment of Safety &Cognitive Performance in Phase 2a Study in mild-to-moderate Alzheimer's Patients

With the amount of education Anavex has on its team I don't see them getting "Late Breaking Communication" status to the CTAD Conference to underperform or come to the table with "bad news" especially with Axovant presenting right before them. If anything I believe Dr. Missling's team may steal the SHOW!!



Anavex Bonus:

Daniel Klamer, PhD
Senior Director of Business Development at Anavex Life Sciences Corp

Summary
Bringing science and business together, I drive promising strategies and initiatives with lasting results.

As a neuroscientist with a PhD in Pharmacology, my background includes years of clinical and pre-clinical research, development of preclinical hypotheses into proven concepts, and supervision of other scientists’ promising projects.

In the business world, I have led key projects from discovery to development, assessed and analyzed new opportunities for acquisition and partnering (often with limited resources), cofounded a startup, attracted and secured investments, and played a central role in deal execution.

With these combined experiences and skills, I:
- Translate ideas into viable commercialization
- Break problems apart and create effective solutions
- Effectively assess the risks and benefits of potential buyouts/mergers
- Identify promising opportunities for partnership
- Build collaborative relationships with clients and partners
- Create and present realistic, executable timelines and plans for strategic projects
- Align and engage teams to highest performance and productivity, and inspire them to achieve key goals

It is a privilege to apply my skills and expertise at Anavex and contribute to new and effective biopharmaceutical treatments for debilitating diseases.

https://www.linkedin.com/profile/view?id=AAEAAADTVioBc7qccNXn8K6uWaJkSLenM46EEas&authType=name&authToken=8QXA&trk=prof-sb-browse_map-name